FC062: Baseline Soluble Immune Checkpoints Predict Relapse Risk in PR3-Anca Vasculitis Following Rituximab Induction Therapy

التفاصيل البيبلوغرافية
العنوان: FC062: Baseline Soluble Immune Checkpoints Predict Relapse Risk in PR3-Anca Vasculitis Following Rituximab Induction Therapy
المؤلفون: Andreas Kronbichler, Gabriele Gamerith, Finn Mildner
المصدر: Nephrology Dialysis Transplantation. 37
بيانات النشر: Oxford University Press (OUP), 2022.
سنة النشر: 2022
مصطلحات موضوعية: Transplantation, Nephrology
الوصف: BACKGROUND AND AIMS We investigated whether soluble immune checkpoints (sICPs) predict treatment-resistance, relapse risk and risk of infections in patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). METHOD Plasma levels of sICPs were measured by enzyme-linked immunosorbent assay from samples obtained at baseline and during follow-up from patients with AAV in the RAVE trial and were correlated with selected clinical outcomes. Log-rank test was used to evaluate survival benefits, and optimal cut-off values of the marker molecules were calculated using Yeldons J. RESULTS Among 95 patients receiving rituximab as induction therapy, lower soluble (s)Lag-3 (3000 pg/mL) were predictive of not achieving remission. Among patients with remission, 32.9% relapsed with a median relapse free survival of 5.64 months. Low baseline values of sTim-3 ( CONCLUSION Rituximab-treated patients achieved remission less frequently when sLag-3 was low and sCD27 was high. Higher expression of sTim-3, sCD27 and sBTLA at baseline was associated with a lower risk of relapse in PR3-ANCA vasculitis following rituximab. These results will require confirmation in future studies, but may contribute to personalized medicine in AAV.
تدمد: 1460-2385
0931-0509
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::e272fcd567da957ed40671cc5d7c565d
https://doi.org/10.1093/ndt/gfac110.002
حقوق: OPEN
رقم الأكسشن: edsair.doi...........e272fcd567da957ed40671cc5d7c565d
قاعدة البيانات: OpenAIRE